Kanti R Rai Selected Research

Kanti R Rai Research Topics

Disease

56	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 01/2023 - 05/2002
10	Neoplasms (Cancer) 01/2021 - 09/2002
8	Leukemia 01/2023 - 09/2002
6	Disease Progression 01/2021 - 12/2002
5	Infections 01/2014 - 05/2002
3	Pneumonia (Pneumonitis) 12/2022 - 12/2016
3	Hairy Cell Leukemia 12/2022 - 03/2003
3	Exanthema (Rash) 12/2022 - 10/2015
3	Non-Hodgkin Lymphoma (Lymphosarcoma) 12/2016 - 09/2002
3	Prolymphocytic Leukemia 02/2013 - 09/2002
3	Lymphoma (Lymphomas) 01/2011 - 01/2002
2	Fever (Fevers) 12/2022 - 10/2005
2	Diarrhea 01/2021 - 12/2016
2	Neutropenia 01/2021 - 12/2016
2	Thrombocytopenia (Thrombopenia) 01/2021 - 03/2007
2	Chromosome Aberrations (Chromosome Abnormalities) 04/2011 - 01/2011
1	Lymphocytosis 01/2023
1	Leukocytosis (Pleocytosis) 01/2021
1	Systemic Lupus Erythematosus (Libman-Sacks Disease) 03/2017
1	Autoimmune Hemolytic Anemia (Cold Agglutinin Disease) 03/2017
1	Colitis 12/2016
1	Arthritis (Polyarthritis) 10/2015
1	Arthralgia (Joint Pain) 10/2015
1	Human Influenza (Influenza) 01/2014
1	Virus Diseases (Viral Diseases) 10/2010
1	Pneumocystis Pneumonia (Pneumocystis carinii Pneumonia) 10/2010
1	Listeria Meningitis 10/2010
1	Colorectal Neoplasms (Colorectal Cancer) 02/2010
1	Inborn Genetic Diseases (Disease, Hereditary) 02/2010
1	Inflammation (Inflammations) 10/2009
1	Second Primary Neoplasms (Neoplasms, Second) 03/2007

Drug/Important Bio-Agent (IBA)

11	fludarabineIBA 02/2013 - 05/2002
10	Immunoglobulins (Immunoglobulin)IBA 01/2021 - 12/2002
8	AntigensIBA 03/2017 - 01/2002
7	Immunoglobulin Heavy Chains (Immunoglobulin Heavy Chain)IBA 07/2014 - 08/2004
7	Proteins (Proteins, Gene)FDA Link 01/2014 - 12/2002
7	Alemtuzumab (Campath)FDA Link 06/2011 - 05/2002
6	AntibodiesIBA 03/2017 - 02/2004
5	Rituximab (Mabthera)FDA Link 12/2016 - 01/2003
4	purineIBA 10/2015 - 09/2002
4	Monoclonal AntibodiesIBA 05/2010 - 02/2004
3	oblimersen (G3139)IBA 11/2009 - 10/2005
3	Cyclophosphamide (Cytoxan)FDA LinkGeneric 11/2009 - 01/2003
3	Alkylating AgentsIBA 04/2006 - 05/2002
2	VemurafenibIBA 12/2022 - 10/2015
2	DNA (Deoxyribonucleic Acid)IBA 01/2021 - 03/2017
2	veltuzumabIBA 01/2016 - 04/2011
2	Interleukin-17 (Interleukin 17)IBA 12/2015 - 04/2012
2	Immunoglobulin Variable RegionIBA 08/2013 - 09/2002
2	CytokinesIBA 11/2011 - 03/2007
2	Chlorambucil (Leukeran)FDA Link 06/2011 - 09/2002
2	Protein Kinases (Protein Kinase)IBA 01/2011 - 01/2011
2	MicroRNAs (MicroRNA)IBA 01/2011 - 02/2010
2	Indicators and Reagents (Reagents)IBA 01/2011 - 11/2003
2	Myosin Heavy Chains (Myosin Heavy Chain)IBA 05/2010 - 12/2008
2	EpitopesIBA 10/2009 - 11/2008
2	Antigen Receptors (Antigen Receptor)IBA 08/2004 - 04/2004
1	ibrutinibIBA 01/2023
1	Agammaglobulinaemia Tyrosine KinaseIBA 01/2023
1	duvelisibIBA 01/2023
1	Phosphotransferases (Kinase)IBA 01/2021
1	EnzymesIBA 01/2021
1	umbralisibIBA 01/2021
1	thiamine triphosphorate (TTP)IBA 01/2019
1	Biomarkers (Surrogate Marker)IBA 01/2019
1	IGF-I-IGFBP-3 complex FDA Link 01/2019
1	CarbohydratesIBA 03/2017
1	idelalisibIBA 12/2016
1	Transaminases (Aminotransferases)IBA 12/2016
1	Bendamustine Hydrochloride FDA Link 12/2016
1	Toll-Like Receptors (Toll-Like Receptor)IBA 04/2015
1	LigandsIBA 04/2015
1	AutoantigensIBA 04/2015
1	NucleotidesIBA 07/2014
1	Lenalidomide (CC 5013)FDA Link 07/2014
1	Hemagglutinins (Hemagglutinin)IBA 01/2014
1	Neutralizing AntibodiesIBA 01/2014
1	Leucine (L-Leucine)FDA Link 01/2014
1	Phenylalanine (L-Phenylalanine)FDA Link 01/2014
1	Peptides (Polypeptides)IBA 08/2013
1	anti-IgMIBA 04/2013
1	AICDA (activation-induced cytidine deaminase)IBA 12/2012
1	Telomerase (Telomerase Reverse Transcriptase)IBA 09/2012
1	InterleukinsIBA 04/2012
1	SuspensionsIBA 04/2012
1	ChromatinIBA 01/2011
1	Cyclin-Dependent Kinases (cdk Proteins)IBA 01/2011
1	DeuteriumIBA 01/2011
1	OligodeoxyribonucleotidesIBA 12/2010
1	OligonucleotidesIBA 02/2009
1	Complementarity Determining Regions (Complementarity Determining Region)IBA 12/2008

Therapy/Procedure

12	Therapeutics 01/2023 - 05/2002
4	Aftercare (After-Treatment) 01/2019 - 05/2002
4	Drug Therapy (Chemotherapy) 06/2011 - 02/2004
2	Subcutaneous Injections 01/2016 - 04/2011
1	Retreatment 12/2022
1	Heterologous Transplantation (Xenotransplantation) 04/2016
1	Injections 01/2016
1	Drug Tapering 10/2015
1	Transplantation 05/2011